Analysis tools are helping cancer centers dig into data about patient treatments to improve care and business decisions.
Harrison Bremerton Oncology (formerly Olympic Hematology & Oncology Associates) is using IntelliDose, a chemotherapy management system from vendor IntrinsiQ to track and analyze its cancer patient treatments as well as to help the Washington state regional cancer clinic compare its therapies with trends at other oncology centers nationwide.
Treatment decisions are made by Harrison Bremerton doctors based on the needs of patients, said Sara Green, and R.N and director of Harrison Bremerton Oncology. The IntelliDose system is used to help manage treatment-related processes and provide key analysis for improved decision making and patient care, she explained.
IntrinsiQ's IntelliDose is a computerized physician order entry and "partial" e-health record system to track patients' cancer treatments, Green said. The IntelliDose software also integrates with full function e-medical record systems from other vendors, such as GE Centricity -- which is being rolled out by Harrison Hospital, which recently acquired the out-patient cancer treatment center, she said.
IntelliDose automates the complex process of calculating, ordering, and administrating chemotherapy. The software pulls data from clinical systems to prescribe and administer chemotherapy, and then delivers treatment data back to patients' EMRs.
IntrinsiQ also captures and stores in a database, oncology treatment data from its customers' IntelliDose systems. That data, representing about 20,000 patients who have been treated by approximately 600 oncologists, allow IntelliDose customers to analyze how their own treatments compare with trends by other cancer centers across the country.
Furthermore, IntrinsiQ’s Web site provides a portal for each client, where authorized users can log in and obtain reports presented as Excel spreadsheets. Oncologists may view only the patient-specific data from their own practice; comparative practice data does not contain personal patient information, said an IntrinsiQ spokeswoman.